KIM
UTHR icon

Kestra Investment Management’s United Therapeutics UTHR Stock Holding History

Kestra Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,118
Closed -$469K – 467
2025
Q3 		$469K Sell
1,118
-2,235
-67% -$752K 0.01% 284
2025
Q2 		$963K Buy
3,353
+1,111
+50% +$332K 0.03% 195
2025
Q1 		$691K Buy
2,242
+534
+31% +$183K 0.02% 221
2024
Q4 		$603K Buy
+1,708
New +$628K 0.02% 202

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Kestra Investment Management's UTHR Position: Q4 2025 in Review

Kestra Investment Management sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 1,118 shares — an estimated $469K sold.

Kestra Investment Management first reported a position in UTHR in Q4 2024 and held it in 4 quarters. The position peaked at $963K in Q2 2025. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Kestra Investment Management reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kestra Investment Management sold 1,118 United Therapeutics shares in Q4 2025, an estimated $469K.
  • Kestra Investment Management first reported a position in United Therapeutics in Q4 2024 and held it in 4 quarters.
  • Kestra Investment Management's United Therapeutics position peaked at $963K in Q2 2025.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Kestra Investment Management's 13F filing for Q4 2025, filed 9 Feb 2026.